Jefferies Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $35
IA
Iambic Therapeutics, Inc. IAM
$14.74
▲ +10.16%
(+$1.36)
⬆️ Above Yest. High
Open
$14.64
Prev Close
$13.38
Day Range
$12.80 – $15.02
52W Range
$9.60 – $25.00
Market Cap
$634.22M
Beta
0.03
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| IPO Date | 2026-10-15 |
| Shares Out. | 47,400,000 |
| Website | iambic.ai ↗ |
| Phone | 16265922520 |
About Iambic Therapeutics, Inc.
Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its proprietary molecular superintelligence platform.
Iambic Therapeutics, Inc. is a publicly traded company under the ticker symbol IAM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📰 Latest News for IAM
Iambic Therapeutics Jumps 17% After-Hours as Wall Street Turns Bullish on Its AI-Powered Drug Discovery Platform
Iambic Therapeutics wins Bank of America backing with 194% upside forecast
Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results
12 Health Care Stocks Moving In Monday's Intraday Session
Iambic to participate in Jefferies Global Healthcare Conference
CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday